LFB Biomanufacturing in the news

LFB is appointing Claire Biot as its new CEO, succeeding Jacques Brom, who oversaw major investments and expansion in plasma-derived products and therapeutic protein manufacturing.

LFB's Board of Directors has proposed Claire Biot as the new CEO, succeeding Jacques Brom, while also welcoming three new board members.

LFB Biomanufacturing and Sartorius are strengthening their partnership to offer coordinated support for biopharmaceutical drug development, reducing technical risks and streamlining processes.

Sartorius and LFB Biomanufacturing expanded their collaboration to offer integrated development solutions for biopharmaceuticals.

Analysis of the growing recombinant antithrombin market and LFB Biomanufacturing's capacity expansion for cell-culture-based protein production.

LFB Biomanufacturing is expanding its Alès site to double production capacity and repatriate US-based pharmaceutical production by 2026.

LFB Biomanufacturing's Alès site produces monoclonal antibodies and recombinant proteins, expanding capacity with new bioreactors and emphasizing high-quality development and production processes.

LFB BioManufacturing in Alès is expanding its bioproduction capacity, producing monoclonal antibody and cell therapy drugs for rare diseases.

Expanded bioproduction capacity in Alès for monoclonal antibodies and rare disease treatments.

LFB Biomanufacturing is investing €20 million to double its Ales site capacity and hire 50 new employees.

LFB Biomanufacturing is investing 20 million euros to double its therapeutic protein production capacity, expand facilities, and enhance analytical services to meet growing market demand and support France's bioproduction sovereignty.

LFB Biomanufacturing is doubling its Alès site capacity to 4,000 liters with a €20M investment and plans to hire 50 more staff by 2026.

LFB Biomanufacturing is investing €20 million to expand its Alès site’s recombinant protein production capacity, supported by government funding and creating new jobs.

LFB Biomanufacturing is expanding its Alès site to double bioproduction capacity for therapeutic proteins, supported by France 2030 funding to strengthen domestic bioproduction and health sovereignty.

LFB Biomanufacturing is investing 20 million euros to double its recombinant protein production capacity in Alès by 2026, expanding facilities and workforce to meet rising biomedicine demand.

LFB Manufacturing is expanding its Alès site to double protein production capacity by 2026, creating 50 jobs and receiving government funding.

LFB Biomanufacturing joined France BioLead to boost France's leadership in bioproduction of therapeutic proteins and antibodies, aiming for excellence by 2030.

LFB Biomanufacturing is scaling up production of the XAV-19 anti-Covid treatment in its Alès facility following a 4.3 million euro capacity expansion.

LFB's Alès biomanufacturing site is producing Covid-19 antibody drug candidates for clinical trials, leveraging its long-standing expertise in recombinant protein production.

Plasma-derived therapies require complex, tightly regulated manufacturing processes involving plasma fractionation and purification, with LFB expanding capacity and developing recombinant protein technologies to meet rising global demand.